Ken Griffin Affimed N.V. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.32 - $0.62 $6,451 - $12,499	20,160 Added 39.07%	71,755 $44,000
Q3 2023 Nov 14, 2023	SELL	$0.46 - $0.65 $5,953 - $8,412	-12,942 Reduced 20.05%	51,595 $24,000
Q2 2023 Aug 14, 2023	BUY	$0.57 - $1.08 $36,786 - $69,699	64,537 New	64,537 $38,000
Q4 2022 Feb 14, 2023	SELL	$1.1 - $2.45 $662,294 - $1.48 Million	-602,086 Reduced 69.37%	265,822 $329,000
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.32 $7.38 Million - $12.5 Million	-3,762,856 Reduced 81.26%	867,908 $1.79 Million
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $1.69 Million - $3.62 Million	744,091 Added 19.14%	4,630,764 $12.8 Million
Q1 2022 May 16, 2022	BUY	$3.69 - $5.65 $237,185 - $363,170	64,278 Added 1.68%	3,886,673 $17 Million
Q4 2021 Feb 14, 2022	SELL	$5.37 - $7.07 $3.65 Million - $4.81 Million	-680,406 Reduced 15.11%	3,822,395 $21.1 Million
Q3 2021 Nov 15, 2021	BUY	$5.54 - $7.51 $694,577 - $941,566	125,375 Added 2.86%	4,502,801 $27.8 Million
Q2 2021 Aug 16, 2021	SELL	$7.78 - $11.4 $723,983 - $1.06 Million	-93,057 Reduced 2.08%	4,377,426 $37.2 Million
Q1 2021 May 17, 2021	BUY	$5.12 - $8.48 $5.18 Million - $8.58 Million	1,011,367 Added 29.24%	4,470,483 $35.4 Million
Q4 2020 Feb 16, 2021	BUY	$3.16 - $7.03 $903,447 - $2.01 Million	285,901 Added 9.01%	3,459,116 $20.1 Million
Q3 2020 Nov 16, 2020	BUY	$3.26 - $4.73 $5.25 Million - $7.62 Million	1,610,408 Added 103.05%	3,173,215 $10.8 Million
Q2 2020 Aug 14, 2020	BUY	$1.58 - $4.63 $2.37 Million - $6.94 Million	1,499,790 Added 2379.98%	1,562,807 $7.21 Million
Q1 2020 May 15, 2020	BUY	$1.44 - $3.02 $37,978 - $79,649	26,374 Added 71.98%	63,017 $100,000
Q4 2019 Feb 14, 2020	SELL	$2.25 - $3.07 $56,868 - $77,594	-25,275 Reduced 40.82%	36,643 $100,000
Q3 2019 Nov 14, 2019	BUY	$2.67 - $3.65 $111,739 - $152,752	41,850 Added 208.54%	61,918 $182,000
Q2 2019 Aug 14, 2019	SELL	$2.6 - $4.21 $233,677 - $378,377	-89,876 Reduced 81.75%	20,068 $58,000
Q1 2019 May 15, 2019	BUY	$3.05 - $4.34 $234,993 - $334,383	77,047 Added 234.21%	109,944 $0
Q3 2018 Nov 13, 2018	SELL	$1.45 - $6.15 $10,857 - $46,051	-7,488 Reduced 18.54%	32,897 $0
Q4 2017 Feb 09, 2018	BUY	$1.23 - $2.3 $49,673 - $92,885	40,385	40,385 $53,000

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account